Oath Research Product Range Rating: Catalog Breadth and Coverage

What drives the product range rating

The Oath Research product range rating lands at 85 of 100 because the catalog clears the rubric's central thresholds — peptide-class breadth, blend capability, GLP completeness — while leaving room for additional dose tiers and broader public test coverage across less-trafficked SKUs.

The class coverage is six. Repair/healing peptides (BPC-157, TB-500, GHK-Cu, KPV) anchor the catalog. GLP-class metabolic peptides cover the full current-generation lineup (semaglutide, tirzepatide marketed as GLP2-T, retatrutide marketed as GLP3-R). Neuro / nootropic (Selank), mitochondrial (SS-31), and GH-axis blends (Tesamorelin + Ipamorelin) round out the breadth.

The blend capability is documented across four multi-component formulations: WOLVERINE (BPC-157 + TB-500), Tesamorelin + Ipamorelin, the three-component BPC-157 + TB-500 + GHK-Cu blend, and the four-component BPC-157 + TB-500 + GHK-Cu + KPV blend. Multi-component blends matter for the rubric because synthesizing or sourcing finished blends is operationally more complex than reselling monomers — it signals real formulation capability rather than a reshipping operation. The WOLVERINE blend tested at 99.39% across 8 batches and the Tesamorelin + Ipamorelin blend at 99.43% across 6 batches indicates the blends are themselves run through the same third-party lab testing program as the monomers.

How wide is Oath Research's product range?

Six peptide classes plus four documented multi-component blends. The rubric grades catalog breadth on five criteria, and the company captures full points on three (multi-component blends offered, GLP-class completeness, peptide-classes-covered scores 27 of 30). The remaining 15 points across dose flexibility and test recency are partially captured (12 of 15 + 6 of 15), with the gaps reflecting per-SKU snapshot capture limits rather than catalog gaps.

What peptides does Oath Research sell?

Verified catalog (selected examples, not exhaustive):

• SS-31 (mitochondrial) — 99.86% purity across 4 batches.
• BPC-157 (repair/healing) — 99.66% purity across 10 batches. Dose options: 5mg, 10mg.
• Selank (neuro/nootropic) — 99.71% purity across 5 batches. Dose options: 5mg, 10mg.
• Tesamorelin + Ipamorelin blend (GH-axis) — 99.43% purity across 6 batches. Dose options: 6/2mg, 10/2mg.
• GLP2-T (Tirzepatide) (GLP-class) — 99.93% purity across 8 batches. Dose options: 10mg, 20mg, 30mg.
• GLP3-R (Retatrutide) (GLP-class) — visible in catalog; specific test data not captured in the snapshot.
• BPC-157 + TB-500 (WOLVERINE blend) — 99.39% purity across 8 batches. Dose option: 5/5mg.
• BPC-157 + TB-500 + GHK-Cu blend — visible in catalog; specific test data not captured.
• BPC-157 + TB-500 + GHK-Cu + KPV blend — visible in catalog; specific test data not captured.

The captured subset is not the complete catalog; peptiderecon's head-to-head cites approximately 40 peptides total, which is a third-party data point we cite with attribution rather than as primary record. Multiple dose options on several SKUs is the dose-flexibility signal that scores into both this category and the value category below.

Where the 15 points went

Three of the 15 missing points sit in peptide-class coverage. Six classes documented passes the ≥5-class threshold for full credit but leaves three points on the table because the next-tier rubric reward (broader coverage into less-trafficked classes) is not yet captured in the snapshot.

Three more sit in dose flexibility. The four SKUs with multi-tier dose options (GLP2-T at 10/20/30mg, BPC-157 at 5/10mg, Selank at 5/10mg, Tesamorelin+Ipamorelin at 6/2mg and 10/2mg) score 12 of 15. The remaining three points are pending broader dose-tier coverage across the catalog.

Nine points sit in test-recency-across-catalog. May 2026 test dates are documented on six of nine catalog-verified entries; specific test data for GLP3-R, the BPC-157 + TB-500 + GHK-Cu blend, and the four-component blend were not captured in the 2026-05-26 snapshot. The points are pending visible test data, not signaling absence — these SKUs are likely tested on the same program but the public-record capture cycle did not extract their COAs at the time of writing.